• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Wednesday

    7/26/23 12:18:54 PM ET
    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACGN alert in real time by email

     

    Wednesday saw 59 companies set new 52-week lows.

    Key Facts About Today's 52-Week Lows:

    • The largest company by market cap to hit a new 52-week low was TC Energy (NYSE:TRP).
    • China SXT Pharmaceuticals (NASDAQ:SXTC) was the smallest company by market cap to set a new 52-week low.
    • AppHarvest (NASDAQ:APPH)'s stock fell the most, as it traded down 19.83% to reach a new 52-week low.
    • XOMA (NASDAQ:XOMA)'s stock made the biggest bounce back, actually moving up 0.0% shortly after hitting a new 52-week low.

    Stocks dropping to new 52-week lows on Wednesday:

    • TC Energy (NYSE:TRP) shares were up 0.49% for the day, having made a 52-week low of $36.44.
    • Apellis Pharmaceuticals (NASDAQ:APLS) stock dropped to a yearly low on Wednesday of $29.70. Shares traded up 4.98%.
    • Cytokinetics (NASDAQ:CYTK) stock drifted up 0.34% on Wednesday morning to hit a new 52-week low of $31.81.
    • Maravai LifeSciences (NASDAQ:MRVI) shares moved down 2.18% on Wednesday to hit a new 52-week low of $11.38, drifting down 2.18%.
    • Monro (NASDAQ:MNRO) shares were down 2.67% for the day, having made a 52-week low of $37.25.
    • Avidity Biosciences (NASDAQ:RNA) shares made a new 52-week low of $8.93 on Wednesday. The stock was down 1.75% for the day.
    • Nexa Res (NYSE:NEXA) shares set a new 52-week low of $4.15. The stock traded up 1.18%.
    • Vertex Energy (NASDAQ:VTNR) shares made a new 52-week low of $4.84 on Wednesday. The stock was up 1.71% for the day.
    • Sharecare (NASDAQ:SHCR) shares were down 5.56% for the day, having made a 52-week low of $1.26.
    • uniQure (NASDAQ:QURE) shares hit a yearly low of $9.39. The stock was down 0.32% on the session.
    • PSQ Holdings (NYSE:PSQH) stock set a new 52-week low of $12.26 on Wednesday, moving down 12.69%.
    • Stoke Therapeutics (NASDAQ:STOK) stock set a new 52-week low of $5.90 on Wednesday, moving down 0.7%.
    • SWK Holdings (NASDAQ:SWKH) stock drifted up 0.12% on Wednesday morning to hit a new 52-week low of $16.07.
    • NGM Biopharmaceuticals (NASDAQ:NGM) stock hit $2.34 on Wednesday morning, setting a new 52-week low for a change of down 0.63%.
    • FibroGen (NASDAQ:FGEN) stock hit $1.84 on Wednesday morning, setting a new 52-week low for a change of down 5.33%.
    • XOMA (NASDAQ:XOMA) stock achieved a new 52-week low on Wednesday morning, hitting $15.26 and moving 0.0% (flat).
    • Complete Solaria (NASDAQ:CSLR) stock hit a yearly low of $4.56. The stock was down 6.12% for the day.
    • Altimmune (NASDAQ:ALT) stock dropped to a yearly low on Wednesday of $2.95. Shares traded up 0.33%.
    • Beyond Air (NASDAQ:XAIR) stock hit a new 52-week low of $3.44. The stock was down 1.0% on the session.
    • ARB IOT Group (NASDAQ:ARBB) stock broke to a new 52-week low of $2.25 on Wednesday. Shares of the company traded down 6.52%.
    • Carmell Therapeutics (NASDAQ:CTCX) stock achieved a new 52-week low on Wednesday morning, hitting $2.97 and moving down 14.93%.
    • Candel Therapeutics (NASDAQ:CADL) stock set a new 52-week low of $1.10 on Wednesday, moving down 0.88%.
    • Leap Therapeutics (NASDAQ:LPTX) stock set a new 52-week low of $2.54 on Wednesday, moving down 6.18%.
    • Aptose Biosciences (NASDAQ:APTO) stock hit $4.01 on Wednesday morning, setting a new 52-week low for a change of down 0.37%.
    • Gulf Resources (NASDAQ:GURE) shares set a new yearly low of $2.32 this morning. The stock was down 1.67% on the session.
    • Acurx Pharmaceuticals (NASDAQ:ACXP) stock hit a new 52-week low of $1.89. The stock was down 2.58% on the session.
    • Cosmos Health (NASDAQ:COSM) stock hit a new 52-week low of $1.66. The stock was 0.0% (flat) on the session.
    • BioCardia (NASDAQ:BCDA) stock hit a new 52-week low of $0.99. The stock was down 2.39% on the session.
    • Vaccinex (NASDAQ:VCNX) stock broke to a new 52-week low of $0.27 on Wednesday. Shares of the company traded up 0.18%.
    • Flora Growth (NASDAQ:FLGC) stock drifted down 2.56% on Wednesday morning to hit a new 52-week low of $2.05.
    • IronNet (NYSE:IRNT) shares moved down 2.58% on Wednesday to hit a new 52-week low of $0.11, drifting down 2.58%.
    • ShiftPixy (NASDAQ:PIXY) shares fell to $1.05 on Wednesday, setting a new 52-week low with a shift of down 3.39%.
    • 60 Degrees (NASDAQ:SXTP) stock hit a yearly low of $2.01. The stock was down 3.05% for the day.
    • Tempest Therapeutics (NASDAQ:TPST) stock hit a yearly low of $0.95. The stock was down 5.11% for the day.
    • Fangdd Network Group (NASDAQ:DUO) shares fell to $0.16 on Wednesday, setting a new 52-week low with a shift of down 4.35%.
    • Sidus Space (NASDAQ:SIDU) shares set a new 52-week low of $0.17. The stock traded down 4.53%.
    • Cyclerion Therapeutics (NASDAQ:CYCN) stock achieved a new 52-week low on Wednesday morning, hitting $2.95 and moving down 4.11%.
    • Bio-Path Hldgs (NASDAQ:BPTH) shares set a new 52-week low of $0.85. The stock traded down 4.04%.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) stock set a new 52-week low of $3.59 on Wednesday, moving down 5.41%.
    • Mallinckrodt (AMEX:MNK) shares fell to $0.41 on Wednesday, setting a new 52-week low with a shift of up 12.72%.
    • Aceragen (NASDAQ:ACGN) stock hit a new 52-week low of $0.59. The stock was up 6.33% on the session.
    • Jeffs Brands (NASDAQ:JFBR) shares hit a yearly low of $0.65. The stock was down 1.6% on the session.
    • Adamis Pharmaceuticals (NASDAQ:ADMP) stock set a new 52-week low of $1.65 on Wednesday, moving up 0.26%.
    • Shineco (NASDAQ:SISI) stock broke to a new 52-week low of $0.22 on Wednesday. Shares of the company traded down 2.61%.
    • 180 Life Sciences (NASDAQ:ATNF) shares fell to $0.85 on Wednesday, setting a new 52-week low with a shift of down 12.75%.
    • Avalo Therapeutics (NASDAQ:AVTX) stock drifted up 4.87% on Wednesday morning to hit a new 52-week low of $0.21.
    • Salarius Pharmaceuticals (NASDAQ:SLRX) shares set a new yearly low of $0.85 this morning. The stock was down 1.15% on the session.
    • Aditxt (NASDAQ:ADTX) stock drifted up 0.5% on Wednesday morning to hit a new 52-week low of $0.39.
    • NeuBase Therapeutics (NASDAQ:NBSE) stock broke to a new 52-week low of $1.35 on Wednesday. Shares of the company traded down 1.36%.
    • First Wave BioPharma (NASDAQ:FWBI) stock achieved a new 52-week low on Wednesday morning, hitting $0.55 and moving down 2.44%.
    • Allarity Therapeutics (NASDAQ:ALLR) stock hit $2.78 on Wednesday morning, setting a new 52-week low for a change of up 0.71%.
    • Esports Entertainment (NASDAQ:GMBL) stock drifted down 5.32% on Wednesday morning to hit a new 52-week low of $0.47.
    • BitNile Metaverse (NASDAQ:BNMV) stock drifted down 5.68% on Wednesday morning to hit a new 52-week low of $0.80.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock dropped to a yearly low on Wednesday of $0.17. Shares traded up 0.21%.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ACGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACGN
    $ACXP
    $ADMP
    $ADTX

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    uniQure N.V.
    $QURE
    1/28/2026$31.00Equal Weight
    Barclays
    Cytokinetics Incorporated
    $CYTK
    1/28/2026$87.00Overweight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    1/28/2026$24.00Equal Weight
    Barclays
    Altimmune Inc.
    $ALT
    1/28/2026$20.00Overweight
    Barclays
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    Apellis Pharmaceuticals Inc.
    $APLS
    1/21/2026$28.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by uniQure N.V.

    SCHEDULE 13G - uniQure N.V. (0001590560) (Subject)

    2/9/26 8:10:32 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    2/6/26 4:12:27 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Altimmune Inc.

    S-8 - Altimmune, Inc. (0001326190) (Filer)

    2/6/26 4:07:05 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Fitzsimmons Peter D bought $251,017 worth of shares (13,350 units at $18.80), increasing direct ownership by 16% to 99,283 units (SEC Form 4)

    4 - MONRO, INC. (0000876427) (Issuer)

    2/5/26 3:32:45 PM ET
    $MNRO
    Automotive Aftermarket
    Consumer Discretionary

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on uniQure with a new price target

    Barclays initiated coverage of uniQure with a rating of Equal Weight and set a new price target of $31.00

    1/28/26 7:20:10 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

    10/18/21 11:55:40 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

    6/30/21 5:11:48 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.

    EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company successfully completed its previously announced tender offer to acquire all outstanding shares of Generation Bio Co. (NASDAQ:GBIO) ("Generation Bio") common stock for a price per share of $4.2913 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR") (together with the Cash Amount, the "Offer Price") and successfully completed its acquisition of Generation Bio. The tender o

    2/9/26 9:53:00 AM ET
    $GBIO
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nexa Achieves 2025 Production, Sales and Costs Guidance, and Provides 2026-2028 Outlook

    Luxembourg, Luxembourg--(Newsfile Corp. - February 6, 2026) - Nexa Resources S.A. (NYSE:NEXA) ("Nexa Resources" or "Nexa" or the "Company") is pleased to announce its operational results for the three-and twelve-month periods ended December 31, 2025. The Company is also providing its production and metal sales guidance for the 2026-2028 period, along with guidance on costs, capital expenditures, and other operating expenses for 2026. The figures presented in this report are preliminary and unaudited. Nexa's financial results for the fourth quarter and full year 2025 are expected to be published on Thursday, February 26, 2026, after trading hours.2025 Summary HighlightsNexa achieved its conso

    2/6/26 9:04:00 AM ET
    $NEXA
    Metal Mining
    Basic Materials

    Jeffs' Brands: KeepZone AI Announces Exclusive Agreement for the Reselling of Counter Underwater Systems for Drug Smuggling and Protecting Offshore Assets

    Tel Aviv, Israel, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd ("Jeffs' Brands" or the "Company") (NASDAQ:JFBR, JFBRW)), a data-driven e-commerce company operating on the Amazon Marketplace expanding into the global homeland security sector through advanced artificial intelligence ("AI") -driven solutions, today announced that its wholly-owned subsidiary, KeepZone AI Inc. ("KeepZone"), has entered into an exclusive reseller agreement (the "Agreement") with DSIT Solutions Ltd. ("DSIT"), a global leader in underwater domain awareness and acoustic intelligence solutions. KeepZone will help lead DSIT's entry into the Mexican market to counter underwater drug smuggling and protect offsh

    2/6/26 7:47:00 AM ET
    $JFBR
    Other Specialty Stores
    Consumer Discretionary

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Angel Matthew

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    2/6/26 4:26:13 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Angel Matthew claimed ownership of 8,268,495 shares (SEC Form 3)

    3 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    2/6/26 4:24:53 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Callos Andrew exercised 15,000 shares at a strike of $23.26 and sold $928,950 worth of shares (15,000 units at $61.93) (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    2/5/26 8:17:30 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Leadership Updates

    Live Leadership Updates

    View All

    PublicSquare Appoints Dusty Wunderlich as Chief Executive Officer

    New Leadership Reinforces Progress Toward Fintech Focus PSQ Holdings, Inc. (NYSE:PSQH) ("PublicSquare" or the "Company"), today announced that Dusty Wunderlich has been appointed CEO, effective immediately, as the Company continues its transition to core fintech businesses, including credit and payments. Mr Wunderlich was recently appointed Chairman of the Board of PublicSquare and will remain in that role. As part of this transition, Michael Seifert has stepped down as Chief Executive Officer and resigned from the Company's Board of Directors, effective January 27, 2026. Mr. Wunderlich was CEO of Credova until PublicSquare acquired the company in March 2024. Given his fintech experienc

    1/29/26 7:30:00 AM ET
    $PSQH
    Advertising
    Consumer Discretionary

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Financials

    Live finance-specific insights

    View All

    Nexa Achieves 2025 Production, Sales and Costs Guidance, and Provides 2026-2028 Outlook

    Luxembourg, Luxembourg--(Newsfile Corp. - February 6, 2026) - Nexa Resources S.A. (NYSE:NEXA) ("Nexa Resources" or "Nexa" or the "Company") is pleased to announce its operational results for the three-and twelve-month periods ended December 31, 2025. The Company is also providing its production and metal sales guidance for the 2026-2028 period, along with guidance on costs, capital expenditures, and other operating expenses for 2026. The figures presented in this report are preliminary and unaudited. Nexa's financial results for the fourth quarter and full year 2025 are expected to be published on Thursday, February 26, 2026, after trading hours.2025 Summary HighlightsNexa achieved its conso

    2/6/26 9:04:00 AM ET
    $NEXA
    Metal Mining
    Basic Materials

    Monro, Inc. Announces Third Quarter Fiscal 2026 Financial Results

    Third Quarter Comparable Store Sales Increased 1.2% Third Quarter Gross Margin Expanded 60 Basis Points Year-over-Year Third Quarter Diluted Earnings per Share of $.35; Adjusted Diluted Earnings per Share1 of $.16 Distributed Third Quarter Fiscal 2026 Cash Dividend of $.28 per Share Monro, Inc. (NASDAQ:MNRO), a leading provider of automotive repair and tire services, today announced financial results for its third quarter ended December 27, 2025. Third Quarter Results Sales for the third quarter of the fiscal year ending March 28, 2026 ("fiscal 2026") decreased 4.0% to $293.4 million, as compared to sales of $305.8 million for the third quarter of the fiscal year ended Marc

    1/28/26 7:30:00 AM ET
    $MNRO
    Automotive Aftermarket
    Consumer Discretionary

    TC Energy provides results of Series 5 and Series 6 conversion elections

    CALGARY, Alberta, Jan. 23, 2026 (GLOBE NEWSWIRE) -- News Release – TC Energy Corporation (TSX:TRP) (NYSE:TRP) (TC Energy or the Company) today announced that 109,800 of its 12,070,593 fixed rate Cumulative Redeemable First Preferred Shares, Series 5 (Series 5 Shares) have been elected for conversion on Jan. 30, 2026 (the Conversion Date), on a one-for-one basis, into floating rate Cumulative Redeemable First Preferred Shares, Series 6 (Series 6 Shares); and 1,089,726 of its 1,929,407 Series 6 Shares have been elected for conversion, on a one-for-one basis, into Series 5 Shares. The Company has provided notice to the holders of its Series 5 Shares and Series 6 Shares (collectively, the Hol

    1/23/26 5:00:00 PM ET
    $TRP
    Natural Gas Distribution
    Utilities

    $ACGN
    $ACXP
    $ADMP
    $ADTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:01:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care